Tanzania Cardiovascular Diseases Therapeutics Market Report 2022 to 2030

Tanzania Cardiovascular Diseases Therapeutics Market Analysis

$ 3999

The Tanzania cardiovascular disease therapeutics market is expected to witness growth from $65 Mn in 2022 to $121 Mn in 2030 with a CAGR of 8.12% for the forecasted year 2022-2030. due to the increased prevalence of cardiovascular diseases as a result of lifestyle changes in Tanzania. Further, the government initiatives to promote cardiovascular health awareness in Tanzania have resulted in market expansion. The Tanzania cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by the end user. Tanga Pharmaceuticals, Nashukuru Pharma, and Sanofi are the major players in the Tanzania cardiovascular disease therapeutics market.

ID: IN10TZPH033 CATEGORY: Pharmaceuticals GEOGRAPHY: Tanzania AUTHOR: Dr. Parul Choudhary

Buy Now

Tanzania Cardiovascular Disease Therapeutics Market Executive Analysis

The Tanzania cardiovascular disease therapeutics market is at around $65 Mn in 2022 and is projected to reach $121 Mn in 2030, exhibiting a CAGR of 8.12% during the forecast period. Tanzania's healthcare industry is expected to generate $15.26 Mn in revenue by 2023. A projected market volume of $22.24 Mn by 2027 is the outcome of revenue growing at a projected annual rate of 9.87% (CAGR 2023–2027). Tanzania has a weak healthcare infrastructure, limited resources, and high rates of maternal and infant mortality, HIV/AIDS, pneumonia, and malaria. The populace of Tanzania also has some of the lowest rates of worldwide access to medical professionals.

The most prevalent cardiovascular-related diseases in Tanzania were hypertensive heart disease (41%), valvular heart diseases (18%), coronary heart diseases (18%), peripartum cardiomyopathy (7%), non-hypertensive dilated cardiomyopathies (6%) in adults, and congenital heart disease (34%) in children. Adults aged 25 to 64 years are particularly impacted by cardiovascular diseases, which account for 13% of all NCD-related deaths in Tanzania. Tanzanian males died at a higher rate than women due to age-standardized CVD mortality rates. Blood clots are prevented from developing in the body by warfarin. If the body is producing blood clots or if there is a health issue that contributes to their formation. Vasodilators ease blood movement through your body by relaxing the blood vessels. If diet and statin therapy are not working, there is a novel class of cholesterol-lowering medications called proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors. They stop the activity of PCSK9, a liver enzyme. The liver's capacity to eliminate LDL (bad) cholesterol is hampered by that protein. An injured or weakened heart can pump more forcefully with the aid of inotropic treatment. It aids in making the cardiac muscle's contractions stronger when given intravenously. Additionally, it relaxes tightened blood arteries to improve blood flow. The rhythm of the heart may also quicken with inotropic treatment.

Tanzania Cardiovascular Disease Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

Tanzania is experiencing an increase in the prevalence of cardiovascular disease as a result of a number of variables, including sedentary lifestyles, unhealthy diets, and rising obesity rates. Consequently, there is an increasing need for efficient therapeutics to control and cure the disease. In order to tackle cardiovascular disease, the Tanzanian government has started a number of programs, including public awareness campaigns, initiatives to encourage healthy lifestyles, and enhancements to healthcare services. The demand for Tanzania's cardiovascular disease therapeutics market is anticipated to rise as a result of these efforts.

Market Restraints

In Tanzania, many people still do not have access to fundamental medical care, which includes cardiovascular disease diagnosis and therapy. This may reduce the desire for treatments for cardiovascular disease. Tanzania's healthcare infrastructure is still being developed and has very few resources and facilities. The distribution and administration of therapeutics for cardiovascular illness may become challenging as a result. Tanzania has little funding for cardiovascular disease therapeutic research and development, which can impede the creation of novel drugs and restrain the expansion of the Tanzania cardiovascular disease therapeutics market.

Competitive Landscape

Key Players

Salama Pharmaceuticals (TZA)
Shelys Pharmaceutical (TZA)
Zenufa Laboratories (TZA)
Tanga Pharmaceuticals (TZA)
Nashukuru Pharma (TZA)
Sanofi
Pfizer
Eli Lilly
Sanofi
Bayer
Bristol-Myers Squibb
Daiichi Sankyo

Healthcare Policies and Regulatory Landscape

The National Health Insurance Fund (NHIF) is Tanzania's primary source of health insurance protection. The diagnosis and treatment of cardiovascular disease are among the medical treatments that are covered by the NHIF. However, the particular plan and package that the person is enrolled in may affect the coverage for cardiovascular disease. The NHIF reimburses healthcare providers for services provided in accordance with a predetermined fee schedule on a fee-for-service basis. Additionally, the NHIF provides healthcare providers with capitation payments, which are set monthly sums paid for each enrolled person independent of the services received. In Tanzania, there are a number of private health insurance providers in addition to the NHIF that handle cardiovascular disease. These private insurance providers frequently provide more thorough coverage for cardiovascular illness and may cover more expensive treatments like heart surgeries. However, many Tanzanians still encounter financial obstacles to getting healthcare services, including treatment for cardiovascular disease, despite the availability of health insurance coverage. Healthcare out-of-pocket costs can be expensive, especially for those without health insurance coverage.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cardiovascular Disease Therapeutics Segmentation

By Disease Indication (Revenue, USD Billion):

Hypertension
Coronary Artery Disease
Hyperlipidaemia
Arrhythmia
Others

By Drug Type (Revenue, USD Billion):

Antihypertensive
Anticoagulants
Antihyperlipidemic
Antiplatelet Drugs
Others

By Route of Administration (Revenue, USD Billion):

Oral
Parenteral
Others

By Drug Classification (Revenue, USD Billion):

Branded Drugs
Generic Drugs

By Mode of Purchase (Revenue, USD Billion):

Prescription-Based Drugs
Over-The-Counter Drugs

By End Users (Revenue, USD Billion):

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.